Search
Feed aggregator
FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier
FTC’s Noncompete Ban Makes Switching Biopharma Jobs Easier 4/25/2024
FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women
FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women 4/25/2024
7 Types of Difficult Bosses and How to Deal With Them
7 Types of Difficult Bosses and How to Deal With Them 4/25/2024
Why Biopharma Companies Avoid Hiring People Who Need Visas
Why Biopharma Companies Avoid Hiring People Who Need Visas 4/25/2024
Where Do We Go From Here? The Future of Women's Health
Where Do We Go From Here? The Future of Women's Health 4/25/2024
Researchers publish final results of key clinical trial for gene therapy for sickle cell disease
In a landmark study, an international consortium led by researchers at Children's Hospital of Philadelphia (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY (exagamglogene autotemcel) for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). The study found that 96.7% of patients in the study did not have any vaso-occlusive crises (VOCs) - a blockage that results in lack of oxygen and painful episodes - for at least one year, and 100% were able to remain hospitalization-free for the same length of time.
Optimal timing maximises Paxlovid benefits for treating COVID-19
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.
The findings suggest that taking Paxlovid three to five days after COVID-19 symptoms emerge may maximise the drug's ability to reduce viral loads, minimise viral spread and reduce viral rebound.
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales
Novartis Beats Q1 Expectations, Raises 2024 Outlook on Strong Drug Sales 4/23/2024
Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win
Sanofi’s $3.7B Principia Buy Starts to Pay Off with Phase III Rilzabrutinib Win 4/23/2024
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates 4/23/2024
ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC
ImmunityBio Wins FDA Approval for First IL-15 Superagonist for NMIBC 4/23/2024
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data
FDA Rejects Abeona’s Epidermolysis Bullosa Cell Therapy, Asks for CMC Data 4/23/2024
Supreme Court Denies Vanda’s Petition in Hetlioz Patent Case Against Teva
Supreme Court Denies Vanda’s Petition in Hetlioz Patent Case Against Teva 4/23/2024
Incyte Breaks Mid-April M&A Lull With Escient Purchase
Incyte Breaks Mid-April M&A Lull With Escient Purchase 4/23/2024
European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
Researchers develop a new way to safely boost immune cells to fight cancer
Cancer is the monster of our society. Last year alone, more than 600,000 people in the United States died from cancer, according to the American Cancer Society. The relentless pursuit of understanding this complex disease has shaped medical progress on developing treatment procedures that are less invasive while still highly effective.
Immunotherapy is on the rise as a possible solution. Immunotherapy involves harnessing the power of the body's immune system to fight against cancer cells.
Alvotech, Teva Enlist New Partner to Expand Access to Humira Biosimilar in US
Alvotech, Teva Enlist New Partner to Expand Access to Humira Biosimilar in US 4/19/2024
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies
FDA Requires Boxed Warning for Secondary Cancers on CAR-T Therapies 4/19/2024
Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC
Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC 4/19/2024
Sanofi Cuts Jobs in US Vaccines Division as Part of Restructuring
Sanofi Cuts Jobs in US Vaccines Division as Part of Restructuring 4/19/2024
World Pharma News
- U.S. FDA approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy for adults with Hemophilia B
- AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
- Researchers publish final results of key clinical trial for gene therapy for sickle cell disease
- Optimal timing maximises Paxlovid benefits for treating COVID-19
- European Commission approves Pfizer's EMBLAVEO® for patients with multidrug-resistant infections and limited treatment options